Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VRCAthis companyVerrica Pharmaceuticals Inc.	$3.56	-4.95×	3.58×	2.49×	-6.41×	-487.1%	90.3%	-33.6%	-50.3%	-72.3%	-38.0%	-19.9%	0.07×	3.05×	-1.54×	2.59×	0.0%	4	-13.81	1	D+
ANTXAN2 Therapeutics, Inc.	$4.05	-0.98×	0.65×	0×	-0.41×	-85.2%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.87×	0.0%	2	8.87	1	C-
BOLDBoundless Bio, Inc.	$2.45	-0.46×	0.27×	0×	-1.02×	-160.5%	0.0%	0.0%	0.0%	-59.0%	-43.0%	-175.9%	0.5×	-0.55×	0×	8.74×	0.0%	1	-3.12	2	C
JSPRJasper Therapeutics, Inc.	$16.57	-0.46×	8.45×	0×	-0.1×	115.9%	0.0%	0.0%	0.0%	-1826.1%	-338.1%	-220.0%	0.3×	0.37×	0×	2.62×	0.0%	0	-45.56	2	C+
NXTCNextCure, Inc.	$6.18	-0.72×	1.15×	0×	-0.36×	10.7%	0.0%	0.0%	0.0%	-159.8%	-141.8%	-123.0%	0.15×	0.39×	0×	4.14×	0.0%	1	-32.51	2	B-
QTTBQ32 Bio Inc.	$9.44	1.37×	0.97×	0.76×	0.25×	-3.3%	100.0%	31.5%	55.5%	71.0%	29.5%	-82.1%	0.37×	-1.05×	15.37×	4.85×	0.0%	5	17.92	5	A+
Peer median	—	-0.46×	0.97×	0×	-0.36×	-3.3%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-123.0%	0.3×	0.37×	0×	4.85×	0.0%	1	-3.12	2	—